SCHEMBL4124063

SCHEMBL4124063

CCc1cc2c(cc1CC)CC(NC(=O)C(F)(F)F)C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.39
CA2 P00918 8/20 0.39
CA12 O43570 7/20 0.39
CA7 P43166 7/20 0.39
CA14 Q9ULX7 7/20 0.39
CA9 Q16790 6/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
ADRB2 P07550 2/20 0.36
ADRB1 P08588 1/20 0.36
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
DRD3 P35462 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607791 0.89 APOB (0.36) CA1CA2CA12CA7CA14
SCHEMBL865550 0.85 KDM4E (0.41) CA1CA2CA12CA7CA14
SCHEMBL4607263 0.84 CA1 (0.43) CA1CA2CA12CA7CA14
SCHEMBL7860302 0.83 ELANE (0.39) CA1CA2CA12CA7CA14
SCHEMBL6359692 0.78 CA1 (0.58) CA1CA2CA12CA7CA14
SCHEMBL7248144 0.78 CA1 (0.43) CA1CA2CA12CA7CA14
SCHEMBL7690123 0.78 CA1 (0.43) CA1CA2CA12CA7CA14
SCHEMBL2283276 0.76 MAPT (0.50) KDM4ELMNAHRH3MTNR1AMTNR1B
SCHEMBL4607688 0.76 MAPT (0.45) CA1CA2CA12CA7CA14
SCHEMBL3441786 0.75 CA1 (0.43) CA1CA2CA12CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP claimed
US-6933410-B2 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2005-08-23 US claimed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US claimed
EP-1487781-B8 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2009-06-03 EP disclosed
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP disclosed
EP-1487781-B1 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2008-07-23 EP disclosed
US-6933410-B2 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2005-08-23 US disclosed
EP-1487781-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES Novartis AG (CH) 2004-12-22 EP disclosed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US disclosed
WO-2003076387-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NAT1, AADAC, IDH3A CA1 2153/4885CA2 1591/4885CA12 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.